RTOG Study to Look at Radiation + Thalidomide for Glioblastoma Multiforme

Publication
Article
OncologyONCOLOGY Vol 13 No 2
Volume 13
Issue 2

Anew Radiation Therapy Oncology Group (RTOG) study will determine whether thalidomide combined with radiation therapy can lengthen survival and time to disease recurrence in adults with glioblastoma multiforme.

Anew Radiation Therapy Oncology Group (RTOG) study will determine whether thalidomide combined with radiation therapy can lengthen survival and time to disease recurrence in adults with glioblastoma multiforme.

Despite important advances in diagnosis and therapy, malignant gliomas tend to recur and progress at or near their original site. A key feature of this type of tumor is the large number of involved blood vessels, which accounts for the tumor’s severity. In the laboratory, however, thalidomide appears to inhibit angiogenesis, said one of the study chairs, W. K. Alfred Yung, MD, of the University of Texas M. D. Anderson Cancer Center. Thalidomide also has further potential because it is associated with minimal toxicity, which may make it suitable for long-term maintenance therapy, he added.

Thalidomide’s New Potential

This RTOG research project has renewed interest in thalidomide, which was developed in the 1950s. It was first used to treat morning sickness in pregnant women and as a sleeping pill until it was discovered that it caused severe birth defects.

Patients who are diagnosed with glioblastoma multiforme (either through biopsy or resection) will begin the combined treatment of radiation therapy and thalidomide at the same time. The radiation therapy will be administered 5 days per week for 6 weeks. Thalidomide therapy, however, may continue until evidence of recurrence or progression is found.

“We hope that the final results will provide a stable and reliable determination of the benefits of the combined therapies along with dosage information in regards to thalidomide,” said Dr. Yung.

Recent Videos
Shwetal Mehta, PhD, describes efforts regarding the development of protein degraders and antibody-drug conjugates in the neuro-oncology field.
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Shwetal Mehta, PhD, highlights novel brain cancer drug development procedures in the clinical lab and pre-clinical arms of the Ivy Brain Tumor Center.
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.